Dana-Farber Cancer Institute

Dr. Shapiro received his undergraduate degree from Columbia University and his Ph.D and M.D. degrees from Weill-Cornell University. He undertook his internal medicine training at Beth Israel Deaconess Medical Center including a final year during which he served as Chief Medical resident. He completed his medical oncology fellowship training at the Dana-Farber Cancer Institute. He has received numerous awards including Phi Beta Kappa, the Alfred Moritz Michaelis Prize from Weill-Cornell Medical College, the George P. Canellas Award for Excellence in Clinical Investigation from the Dana-Farber Cancer Institute and the 2013 Michaele Christian Oncology Drug Development Award from NCl-CTEP. Dr. Shapiro has been a faculty member at Harvard Medical School since 1992 as an Instructor in Medicine and later an Associate Physician at Brigham and Women's Hospital. In 1998 he was named an Assistant Professor of Medicine and was promoted to Associate Professor of Medicine at Harvard in 2008.

Since 2007, he has been the leader of the Early Drug Development Center of the Dana-Farber Cancer Institute, where he has worked to build a comprehensive Phase I program in early cancer drug development, particularly in solid tumors. The Center enrolls approximately 200 patients per year in early phase clinical trials of novel investigational agents, including cell cycle inhibitors, such as those targeting CDKs and Aurora kinases, as well as DNA damage response modulators that inhibit checkpoint kinases and PARP. The Center has also conducted studies of MET/ALK, Pl3K, HSP90 and angiogenesis inhibitors, often with proof-of-mechanism endpoints.  Several trials are addressing the combination of targeted agents with immune checkpoint blockade.   Finally, Dr. Shapiro also directs translational laboratory-based research focused on cell cycle therapeutics and their interaction with the DNA damage response.